Supernus Pharmaceuticals ... (SUPN)
| Bid | 26 |
| Market Cap | 1.82B |
| Revenue (ttm) | 661.82M |
| Net Income (ttm) | 73.86M |
| EPS (ttm) | 1.32 |
| PE Ratio (ttm) | 24.64 |
| Forward PE | 12.78 |
| Analyst | Hold |
| Ask | 35.48 |
| Volume | 269,211 |
| Avg. Volume (20D) | 629,704 |
| Open | 31.72 |
| Previous Close | 32.48 |
| Day's Range | 31.34 - 32.63 |
| 52-Week Range | 25.53 - 40.28 |
| Beta | 0.90 |
About SUPN
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy tr...
Analyst Forecast
According to 2 analyst ratings, the average rating for SUPN stock is "Hold." The 12-month stock price forecast is $36, which is an increase of 10.70% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
47 minutes ago · accessnewswire.com
Supernus Pharmaceuticals, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - SUPNNEW YORK, NY / ACCESS Newswire / May 1, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:S...
